9th ISHL Highlights media
9th ISHL Highlights media published on
November 4, 2013
Dr. Engert, chairman of the 2013 9th International Symposium on Hodgkin Lymphoma, provides an overview of the presentations and scientific workshops covered at the meeting in Cologne, Germany.
9th ISHL Highlights media published on
November 4, 2013
Dr. Armitage discusses the key elements to the treatment of early stage Hodgkin Lymphoma, evaluating the use of chemotherapy and PET scans as potential predictors to patient outcomes.
9th ISHL Highlights media published on
November 4, 2013
Dr. Armitage discusses brentuximab vedotin and its impact on the treatment paradigm of Hodgkin lymphoma.
9th ISHL Highlights media published on
November 4, 2013
Dr. Cheson discusses long-term follow up and survivorship in patients with Hodgkin lymphoma including long-term consequences of the treatment, quality of life, and psychosocial/psychosexual function.
9th ISHL Highlights media published on
November 4, 2013
Dr. Federico discusses the evolution of risk assessment in patients with advanced-stage Hodgkin lymphoma and the role it has in the design of clinical trials and developing treatment guidelines.
9th ISHL Highlights media published on
November 4, 2013
Dr. Hutchings provides an overview of PET/CT treatment in advanced and early-stage Hodgkin lymphoma with discussion of two related pivitol trials recently published, the EU H10 and the RAPID.
9th ISHL Highlights media published on
November 4, 2013
Dr. Steidl discusses a pivotal Phase III randomized controlled clinical trial to predict overall survival in advanced-stage classical Hodgkin lymphoma.
9th ISHL Highlights media published on
November 4, 2013
Dr. von Tresckow discusses data from current trials in the treatment of relapsed/refractroy Hodgkin lymphoma, including HDR2 and H96, and new agents that can be used in salvage therapy.
Results 1 - 8 of 8